Eli Lilly and Company (LLY)vsPACS Group, Inc. (PACS)
LLY
Eli Lilly and Company
$948.45
-2.72%
HEALTHCARE · Cap: $869.41B
PACS
PACS Group, Inc.
$33.59
-0.12%
HEALTHCARE · Cap: $5.32B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 1266% more annual revenue ($72.25B vs $5.29B). LLY leads profitability with a 35.0% profit margin vs 3.6%. PACS appears more attractively valued with a PEG of 1.00. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
PACS
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+72.9%
Fair Value
$144.37
Current Price
$33.59
$110.78 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 108 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Earnings expanding 57.2% YoY
Every $100 of equity generates 23 in profit
Growing faster than its price suggests
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 27.2x book value
Moderate valuation
3.6% margin — thin
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : PACS
The strongest argument for PACS centers on EPS Growth, Return on Equity, PEG Ratio. Revenue growth of 12.4% demonstrates continued momentum. PEG of 1.00 suggests the stock is reasonably priced for its growth.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : PACS
The primary concerns for PACS are P/E Ratio, Profit Margin, Free Cash Flow. Debt-to-equity of 4.93 is elevated, increasing financial risk. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
LLY profiles as a growth stock while PACS is a value play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.48 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 58/100), backed by strong 35.0% margins and 55.5% revenue growth. PACS offers better value entry with a 72.9% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →PACS Group, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
PACS Group, Inc. is a prominent technology solutions provider dedicated to improving operational efficiency across diverse industries through innovative software and hardware systems. The company emphasizes research and development, positioning itself to leverage emerging technological trends and drive digital transformation. With robust strategic partnerships and a significant market presence, PACS Group is well-equipped to enhance its competitive advantage, making it an attractive investment opportunity for institutional investors seeking growth in the rapidly evolving technology landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?